Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Siccoral is a fixed-dose combination oropharyngeal spray containing the non-steroidal anti-inflammatory drug (NSAID) benzydamine hydrochloride and the antiseptic chlorhexidine gluconate. Benzydamine provides local analgesic, anesthetic, and anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines (such as TNF-α and IL-1β) and stabilizing cell membranes. Chlorhexidine acts as a broad-spectrum antiseptic by disrupting bacterial cell membranes. Siccoral is primarily used for the symptomatic treatment of inflammatory conditions of the mouth and throat, including pharyngitis, tonsillitis, gingivitis, and stomatitis. In clinical settings, it has been evaluated for its efficacy in preventing and relieving postoperative sore throat (POST) following endotracheal intubation, where it is typically administered as a pre-induction spray.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benzydamine + chlorhexidine (Drogsan Pharmaceuticals).